Trial Profile
A feasibility study of Krestin (PSK) plus TS-1 combination therapy for resectable gastric cancer.
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 May 2016
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Polysaccharide K (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 13 May 2016 New trial record